Forskning
Udskriv Udskriv
Switch language
Region Hovedstaden - en del af Københavns Universitetshospital
E-pub ahead of print

European Academy of Neurology/European Alzheimer's Disease Consortium position statement on diagnostic disclosure, biomarker counseling, and management of patients with mild cognitive impairment

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

DOI

  1. Episodic hyperCKaemia may be a feature of α-methylacyl-coenzyme A racemase deficiency

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Increased short- and long-term mortality following infections in dementia: a nationwide registry-based cohort study

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Early indicators of primary brain tumours: a population-based study with 10 years’ follow-up

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  4. Headache at onset of first-ever ischemic stroke: Clinical characteristics and predictors

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  5. A European Academy of Neurology guideline on medical management issues in dementia

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  1. Increased short- and long-term mortality following infections in dementia: a nationwide registry-based cohort study

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Mortality in Dementia from 1996 to 2015: A National Registry-Based Cohort Study

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Undersøgelse af spinalvæske ved udredning for kognitiv svækkelse og demens

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

Vis graf over relationer

BACKGROUND AND PURPOSE: Careful counseling through the diagnostic process and adequate postdiagnostic support in patients with mild cognitive impairment (MCI) is important. Previous studies have indicated heterogeneity in practice and the need for guidance for clinicians.

METHODS: A joint European Academy of Neurology/European Alzheimer's Disease Consortium panel of dementia specialists was appointed. Through online meetings and emails, positions were developed regarding disclosing a syndrome diagnosis of MCI, pre- and postbiomarker sampling counseling, and postdiagnostic support.

RESULTS: Prior to diagnostic evaluation, motives and wishes of the patient should be sought. Diagnostic disclosure should be carried out by a dementia specialist taking the ethical principles of "the right to know" versus "the wish not to know" into account. Disclosure should be accompanied by written information and a follow-up plan. It should be made clear that MCI is not dementia. Prebiomarker counseling should always be carried out if biomarker sampling is considered and postbiomarker counseling if sampling is carried out. A dementia specialist knowledgeable about biomarkers should inform about pros and cons, including alternatives, to enable an autonomous and informed decision. Postbiomarker counseling will depend in part on the results of biomarkers. Follow-up should be considered for all patients with MCI and include brain-healthy advice and possibly treatment for specific underlying causes. Advice on advance directives may be relevant.

CONCLUSIONS: Guidance to clinicians on various aspects of the diagnostic process in patients with MCI is presented here as position statements. Further studies are needed to enable more evidence-based and standardized recommendations in the future.

OriginalsprogEngelsk
TidsskriftEuropean Journal of Neurology
Sider (fra-til)ahead of print brit 150121
ISSN1351-5101
DOI
StatusE-pub ahead of print - 2021

Bibliografisk note

© 2020 The Authors. European Journal of Neurology published by John Wiley & Sons Ltd on behalf of European Academy of Neurology.

ID: 61757468